JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
US$196.52
0.00%
(0.00) 1 天
4月24日, GMT-4 16:00:01 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 JAZZ 生成关键数据洞见…
市值
一二〇.九八亿
平均成交量
八九.六三万
成交量
七九三.〇〇
52 周最高价
US$207.48
52 周最低价
US$97.50
每股收益
-US$5.87
Beta 版
〇.二三
流通股数
六一五六.〇〇万
员工人数
二八九〇
新闻报道
来自全网
Investing.com
·
33分钟前
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer
资料
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Jazz Pharmaceuticals PLC简介